AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-86. (Cancelled)

87. (New) A process for preparing a lipid suspension, comprising:

(a) contacting at least two lipids with a first non-aqueous solvent which causes the lipids to dissolve and form a lipid solution;

(b) contacting the lipid solution with a second non-aqueous solvent which causes the lipids to precipitate out as a solid lipid blend;

(c) collecting the solid lipid blend;

(d) contacting the solid lipid blend with a third non-aqueous solvent which causes the lipid blend to dissolve to form a lipid blend solution;

(e) contacting the lipid blend solution with an aqueous solution to yield a lipid suspension.

88. (New) The process of Claim 87, wherein each of the lipids has a gel to liquid crystalline phase temperature and wherein the lipid blend solution of step (d) is heated to a temperature that is about equal to or above the highest gel to liquid crystalline phase temperature of the lipids.

89. (New) The process of Claim 87, wherein the first non-aqueous solvent is a mixture of methanol and toluene.

90. (New) The process of Claim 87, wherein the second non-aqueous solvent is methyl *t*-butyl ether.

91. (New) The process of Claim 87, wherein the third non-aqueous solvent is selected from propylene glycol, ethylene glycol, and polyethylene glycol 300.

92. (New) The process of Claim 91, wherein the third non-aqueous solvent is propylene glycol.

93. (New) The process of Claim 87, wherein the aqueous solution is water, saline, a saline and glycerin mixture, or a saline and glycerin and non-aqueous solvent mixture.

94. (New) The process of Claim 93, wherein the aqueous solution is a saline and glycerin mixture.

95. (New) The process of Claim 93, wherein the aqueous solution is a saline, glycerin, and propylene glycol mixture.

96. (New) The process of Claim 87, wherein the first non-aqueous solvent is a mixture of methanol and toluene and wherein the second non-aqueous solvent is methyl *t*-butyl ether.

97. (New) The process of Claim 87, wherein the third non-aqueous solvent is propylene glycol and wherein the aqueous solution is a saline, glycerin, and propylene glycol mixture.

98. (New) The process of Claim 96, wherein the third non-aqueous solvent is propylene glycol and wherein the aqueous solution is a saline, glycerin, and propylene glycol mixture.

99. (New) A process according to Claim 98, wherein 6.8 mg/mL of sodium chloride are present, 0.1 mL/mL of glycerin are present, 0.1 mL/mL of propylene glycol are present, and about 0.75 to 1.0 mg/mL of the lipid blend are present in the lipid suspension.

100. (New) A process according to Claim 87, wherein the third non-aqueous solvent is heated to a temperature of about 30 to 70°C prior to contacting with the solid lipid blend.

101. (New) A process according to Claim 87, wherein the third non-aqueous solvent is heated to a temperature of about 50 to 55°C prior to contacting with the solid lipid blend.

102. (New) A process according to Claim 87, wherein in step (d) the ratio of solid lipid blend to third non-aqueous solvent is from about 5 mg of solid lipid blend per mL of non-aqueous solvent to about 15 mg/mL of solid lipid blend per mL of non-aqueous solvent.

103. (New) A process according to Claim 102, wherein the ratio of solid lipid blend to third non-aqueous solvent is about 10 mg/mL.

104. (New) A process according to Claim 87, wherein in step (e), the aqueous solution is heated to a temperature of about 45 to 60°C prior to contacting with the lipid blend solution.

105. (New) A process according to Claim 104, wherein the aqueous solution is heated to a temperature of about 50 to 55°C prior to contacting with the lipid blend solution.

106. (New) A process according to Claim 89, wherein the lipid blend solution is heated to a temperature of at least about 67°C.

107. (New) A process according to Claim 89, wherein step (d) of the process further comprises:
filtering the lipid blend solution through a sterilizing filter to form a filtered lipid blend solution.

108. (New) A process according to Claim 107, wherein step (d) of the process further comprises:
filtering the filtered lipid blend solution through a second sterilizing filter to form a twice filtered lipid blend solution.

109. (New) A process according to Claim 108, wherein the sterilizing filters are at a temperature of from about 70 to 80°C.

110. (New) A process according to Claim 109, wherein 0.2μm hydrophilic filters are used.

111. (New) A process according to Claim 107, wherein the process further comprises: dispensing the filtered lipid blend solution into a vial.

112. (New) A process according to Claim 111, wherein the process further comprises: exchanging the headspace gas of the vial with a perfluorocarbon gas.

113. (New) A process according to Claim 112, wherein the perfluorocarbon gas is perfluoropropane.

114. (New) A process according to Claim 113, wherein exchange of headspace gas is performed using a lyophilizing chamber.

115. (New) A process according to Claim 112, wherein the process further comprises: sterilizing the vial.

116. (New) A process according to Claim 115, wherein the vial is sterilized at about 126-130°C for 1 to 10 minutes.

117. (New) The process of Claim 87, 88, 96, 97, 100, 102 or 104 wherein the lipids comprise:

(a) 1,2-dipalmitoyl-*sn*-glycero-3-phosphatidylcholine;

(b) 1,2-dipalmitoyl-*sn*-glycero-3-phosphotidic, mono sodium salt; and,

(c) *N*-(methoxypolyethylene glycol 5000 carbamoyl)-1,2-dipalmitoyl-*sn*-glycero-3-phosphatidylethanolamine, mono sodium salt.